Pages that link to "Q33782296"

The following pages link to Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage (Q33782296):

Displaying 33 items.

• Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). (Q33215103) (← links)
• Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. (Q33781055) (← links)
• Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage (Q33783714) (← links)
• Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1 (Q33786049) (← links)
• Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains (Q33788810) (← links)
• Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees (Q33810203) (← links)
• A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. (Q33822395) (← links)
• Characterization of primary isolate-like variants of simian-human immunodeficiency virus (Q33825229) (← links)
• Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope (Q33839402) (← links)
• Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques (Q33842286) (← links)
• Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate (Q33851094) (← links)
• Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection (Q33874171) (← links)
• Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity (Q33987391) (← links)
• Neutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count (Q33998352) (← links)
• The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection (Q34317025) (← links)
• Neutralizing antiviral antibody responses (Q34419527) (← links)
• A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. (Q34444535) (← links)
• Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels (Q34546037) (← links)
• Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys (Q35077793) (← links)
• Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex (Q35621250) (← links)
• Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. (Q35634988) (← links)
• Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants (Q37034798) (← links)
• Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. (Q37356010) (← links)
• Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins (Q37730028) (← links)
• Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni (Q39243308) (← links)
• Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i (Q39549660) (← links)
• Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. (Q39577692) (← links)
• Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. (Q39579973) (← links)
• Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1 (Q39580513) (← links)
• Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course (Q39605628) (← links)
• Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. (Q39610187) (← links)
• Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction (Q39682713) (← links)
• Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients (Q39789278) (← links)